[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre hospitalier de l'Université de Montréal (CHUM)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":625},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,54,80,101,134,155,176,201,229,256,282,304,325,350,373,392,418,445,476,500,524,542,558,581,609],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100520020","effects-of-probiotics-in-amyotrophic-lateral-sclerosis-frontotemporal-dementia-spectrum-disorder-als-ftdsd-patients-100520020",false,"NCT06051123","Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients","Effects of Probiotics on Lipidomic Profile and Disease Evolution in ALS-FTDSD Patients: A Randomized Multicenter, Double-blind, Phase II, Placebo-controlled, Parallel Trial.","PROBIOTIC","Inclusion criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for enrolment into the study:ALS-FTDSD participants\n\n1. Aged 18 years old or greater.\n2. Diagnosis of ALS by El Escorial Criteria revised (possible, probable, probable with lab support and definite).\n3. Onset of weakness or speech impairment no more than 24 months before randomization.\n4. ALSFRS-R equal or superior to 24\u002F48 at screening, with no more than one subscore under 2\u002F4.\n5. SVC greater than or equal to 60% predicted for sex, age and height at screening.\n6. Note on FTD Symptoms: The presence of FTD symptoms is not a requirement for inclusion in this study. Participants with a diagnosis of ALS, whether or not accompanied by FTD symptoms, are eligible for inclusion. No prior or screening diagnosis of FTDSD is required.\n7. Subject has an informant\u002Fcaregiver who has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.\n8. Participants apt to comprehend and sign the ICF.\n9. Participants of child-bearing potential must have a negative serum pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n\n   * Abstinence or agrees to use contraception if planning to become sexually active.\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n10. Willing to maintain eating habits throughout the study.\n11. Willing to refrain from consuming probiotic supplements and food containing added probiotics and\u002For prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.\n\nHealthy controls:\n\n1. Aged 18 years old or greater.\n2. Able to comprehend and willing to sign ICF.\n3. Participants of child-bearing potential must have a negative serum pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n\n   * Abstinence or agrees to use contraception if planning to become sexually active.\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n4. Willing to maintain eating habits throughout the study.\n5. Willing to refrain from consuming probiotic supplements and food containing added probiotics and\u002For prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study.\n\nInformant\u002Fcaregiver\n\n1. Aged 18 years old or greater.\n2. Has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS.\n3. Able to comprehend and willing to sign ICF\n\nExclusion criteria:\n\nSubjects with any of the following characteristics\u002Fconditions will not be included in the study:\n\nALS-FTDSD participants\n\n1. Use of respiratory support (non-invasive ventilation or mechanical respiratory support) at screening.\n2. Significant medical condition or behavioral issues that could interfere with participation in the clinical trial in the principal investigator's opinion.\n3. Use of a feeding tube at randomization.\n4. Use of lipid-lowering drugs for less than 3 months before randomization.\n5. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.\n6. Use of edaravone with stable dosage for less than 2 months before randomization.\n7. Use of riluzole with stable dosage for less than 1 month before randomization.\n8. Introduction of edaravone or riluzole during the clinical trial.\n9. Immunodeficiency (immune-compromised and immune-suppressed participants, e.g., AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants).\n10. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding.\n11. Use of probiotics other than the study medication in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period.\n12. Use of any antibiotic drug in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period.\n13. Milk and soy allergy, or severe lactose intolerance.\n14. Currently enrolled in another clinical trial.\n\nHealthy controls:\n\n1. Use of lipid-lowering drugs for less than 3 months before randomization.\n2. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines.\n3. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding. Note: participants will not take the IP or placebo, but pregnancy is a major factor that could affect lipidomic profiling.\n4. Use of probiotics in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.\n5. Use of any antibiotic drug in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group.\n6. Milk and soy allergy, or severe lactose intolerance. Note: Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. We aim to exclude allergies, so participants are maintained on standard diet.\n7. Currently enrolled in another clinical trial.",true,"ALL","18 Years",{"count":22,"type":23},150,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.",[29,30,31],"ALSFTD","ALS (Amyotrophic Lateral Sclerosis)","Frontal Temporal Dementia (FTD)",[33,34,35,36,37,38,39,40],"ALS","FTD","motor function","probiotics","lipidomics","metabolites","neurofilament","microbiome","RECRUITING","2026-06-26",{"date":44,"type":45},"2026-06-30","ACTUAL",{"date":47,"type":45},"2024-01-01",{"date":49,"type":23},"2027-02",{"name":51,"class":52},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",3,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":19,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100643102","scar-management-through-serial-casting-100643102","NCT07645664","Scar Management Through Serial Casting","Inclusion Criteria:\n\n* adult burn survivors who have two scars that meet the diagnostic criteria of a HSc (erythema index greater than 300 and thickness greater than 2.034 mm) and with no more than 0.5 mm thickness difference between each other;\n* are proficient in English and\u002For French;\n* provide informed consent.\n\nExclusion Criteria:\n\n* patients who sustained electrical or cold injury;\n* formed keloid scars or have only mature scars (erythema index less than 300);\n* have a a dermatological condition that could interfere with measurement reliability (eczema, psoriasis);\n* have a cognitive\u002Fpsychiatric condition that could impaired understanding of the consent process or adherence to protocol procedures.","16 Years",{"count":62,"type":23},38,[26],"Scar management remains one of the major clinical challenges for burn survivors with hypertrophic scars. Beyond their visible appearance, hypertrophic scars can significantly impair physical function, reduce life satisfaction, and affect overall quality of life. According to the results of a recently completed study, the application of serial casts appears promising for the treatment of hypertrophic scars in adults who have survived a burn injury. However, this therapeutic approach has not yet been evaluated objectively in terms of scar characteristics within the context of a study with sufficient statistical power. The present project is the first study with sufficient statistical power to objectively evaluate the beneficial effects of serial casting on the characteristics of hypertrophic scars in adult burn survivors. The objective of this study is to characterize changes in thickness, elasticity, vascularization, transepidermal water loss (TEWL), itching, and pain in hypertrophic burn scars in adults after one week of treatment with serial dressings, compared to an intra-individual control scar. Our hypothesis is that relative to baseline measures the scar thickness (primary outcome), erythema index, TEWL, itch, and pain will decrease at treatment sites compared to control sites. Conversely, elasticity will increase at the treatment sites compared to control sites. This will be a prospective, longitudinal, evaluator-blinded, randomized intra-individual controlled trial.",[66],"Burn Scar",[68,69,70],"Burns","Burn Rehabilitation","Serial Casting","NOT_YET_RECRUITING","2026-06-09",{"date":74,"type":45},"2026-06-12",{"date":76,"type":23},"2026-06-01",{"date":78,"type":23},"2028-11",{"name":51,"class":52},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100633307","joint-effort-20--evaluation-among-general-population-100633307","NCT07524985","Joint Effort 2.0 : Evaluation Among General Population","\" Joint Effort 2.0 \" Une Application Mobile de prévention et de réduction Des méfaits: évaluation auprès de Consommateurs de Cannabis","Inclusion Criteria:\n\n* Aged 18 years old or older\n* Be an active non-medical cannabis user (ie. self reported past month usage)\n* Understand, read and write French\n* Own a smartphone (iPhone)\n\nExclusion Criteria:\n\n* None",{"count":88,"type":23},110,[26],"This study aims to evaluate a mobile app designed to promote the safe use of cannabis among adult users in Quebec.",[92],"Cannabis Use",{"date":94,"type":45},"2026-06-03",{"date":96,"type":45},"2026-04-30",{"date":98,"type":23},"2027-04",{"name":51,"class":52},1,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":100},"100573228","phase-1-surgery-after-verifying-existing-disease-in-locally-advanced-operable-lung-cancer-a-pilot-study-100573228","NCT06743555","Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study","Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer (SAVED LUNG Study): A Pilot Study","SAVED LUNG","Inclusion Criteria:\n\n* \\> 18 years of age\n* The participant has provided documented informed consent for the trial.\n* Histologically confirmed (by core biopsy) NSCLC and confirmed clinical stages II-III (excluding N2) NSCLC (AJCC 8th edition) amenable to receive neoadjuvant chemo-immunotherapy defined by: nivolumab 3mg\u002Fkg Q3W in combination with platinum doublet chemotherapy (cisplatin or carboplatin with paclitaxel or pemetrexed Q3W) for 3 cycles.\n* PD-L1 tumor proportion score \\>50%\n* Has no history of immunodeficiency, HBV, HCV, HIV.\n* For female participants:\n\n  1. Has no active pregnancy (Refer to \"Female participants\").\n  2. For a woman of child-bearing potential (WOCBP), use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least 180 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) to others or freeze\u002Fstore for her own use for the purpose of reproduction during this period.\n  3. A WOCBP must have a negative highly sensitive pregnancy test (\\[urine or serum\\] as required by local regulations) within either 24 hours (urine) or 72 hours (serum) before the first dose of study intervention.\n  4. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has adequate hematological, renal and hepatic function per Investigator discretion required for platinum-doublet chemotherapy plus immunotherapy.\n* Has signed the written consent.\n\nExclusion Criteria:\n\n* Has one of the following tumor locations\u002Ftypes:\n\n  1. NSCLC involving the superior sulcus\n  2. Large cell neuro-endocrine cancer (LCNEC)\n  3. Sarcomatoid tumor\n* Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has had an allogenic tissue\u002Fsolid organ transplant.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.\n* Has a known additional malignancy that is progressing or requires active treatment within the past (5 years). Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, bladder carcinoma, or carcinoma in situ (eg, in situ cervical cancer or breast carcinoma) that have undergone potentially curative therapy are not excluded.",{"count":110,"type":23},14,[112],"PHASE1","The SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical response following neoadjuvant platinum-doublet chemotherapy and immunotherapy. Participants are randomized to observation or surgery after rigorous restaging, with primary endpoints focusing on safety and feasibility. Secondary objectives include rates of cross-over to surgery, event-free survival, and overall survival, while exploratory endpoints examine ctDNA clearance and its association with clinical response.",[115,116,117,118,119],"Non-Small Cell Lung Cancer","Immunotherapy","Neoadjuvant Therapy","Thoracic Surgery","Complete Response",[121,122,123,124,125],"NSCLC","Neoadjuvant immunotherapy","Complete response","Surveillance","PD-L1","2026-04-24",{"date":128,"type":45},"2026-04-28",{"date":130,"type":23},"2026-05-01",{"date":132,"type":23},"2032-02",{"name":51,"class":52},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":100},"100288987","corneal-collagen-crosslinking-to-increase-the-resistance-of-the-support-graft-of-the-kpro-type-i-against-corneal-melting-100288987","NCT03041883","Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting","Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting","CXL-KPro","Inclusion Criteria:\n\n* Candidate for KPro type I\n* Capacity to give written consent\n* Ability to be followed for the duration of the study\n\nExclusion Criteria:\n\n* Participation in another interventional study\n* Failure to wear a therapeutic contact lens due to abnormalities of the eyelids.\n* Inability to give written consent\n\nContraindications to the KPro type I:\n\n* Severe dryness with keratinization of the ocular surface\n* Intraocular tumor\n* Terminal glaucoma\n* Inoperable retinal detachment\n* Phthisis bulbi","80 Years",{"count":144,"type":23},40,[26],"The purpose of this study is to demonstrate the safety and efficacy of the corneal collagen crosslinking with riboflavin and ultraviolet A in aim to increase the resistance of the graft used as a support for the Boston keratoprosthesis (KPro) type I against corneal melting (keratolysis or sterile necrosis).",[148],"Corneal Melting in Boston Keratoprosthesis Type I",{"date":128,"type":45},{"date":151,"type":45},"2017-01-04",{"date":153,"type":23},"2028-01",{"name":51,"class":52},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":142,"enrollmentInfo":161,"targetDuration":4,"studyType":24,"phases":163,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":100},"100453166","phase-1-topical-infliximab-in-eyes-with-penetrating-keratoplasty-100453166","NCT05180994","Topical Infliximab in Eyes With Penetrating Keratoplasty","Inclusion Criteria:\n\n* Age between 18 and 80 years;\n* First corneal transplant surgery;\n* Capable of providing informed consent;\n* Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Past corneal transplant (any technique);\n* Advanced glaucoma or macular disease;\n* Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);\n* Malignancy diagnosed in the past 5 years (any kind);\n* Demyelinating disease;\n* History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);\n* Pregnancy or breastfeeding;\n* Allergy to infliximab or to a compound of its topical formulation;\n* Significant anomaly of complete blood count or hepatic enzymes;\n* Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.",{"count":162,"type":23},50,[112,164],"PHASE2","Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.",[167],"Glaucoma Following Surgery","2026-04-23",{"date":170,"type":45},"2026-04-27",{"date":172,"type":45},"2022-05-01",{"date":174,"type":23},"2028-03-01",{"name":51,"class":52},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":142,"enrollmentInfo":182,"targetDuration":4,"studyType":24,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":100},"100380391","the-role-of-transscleral-cyclophotocoagulation-in-patients-undergoing-a-boston-keratoprosthesis-100380391","NCT04232982","The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis","Inclusion Criteria:\n\n* Adults patients\n* Able to give an informed consent\n* Capable of being followed during the study\n* Candidate for the Boston keratoprosthesis type I\n\nExclusion Criteria:\n\n* Patients younger than 18 years old or older than 80 years old\n* Unable to give an informed consent\n* Participating to another interventional glaucoma study\n* Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit.\n* Unable to wear a therapeutic contact lens secondary to eyelid malformation\n* Severe Ocular surface Disease with keratinization\n* Intra-ocular tumor\n* Terminal Glaucoma\n* Phthisis bulbi\n* Ocular albinism",{"count":183,"type":23},20,[26],"The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success.\n\nGlaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure.\n\nIn order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye.\n\nThe transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis.\n\nOur hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis .\n\nMETHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist.\n\nFollowing their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.",[187,188,189],"Glaucoma","Eye Diseases","Cornea Disease",[191,192,193,194],"Boston keratoprosthesis","Transscleral cyclophotocoagulation","Micropulse transscleral cyclophotocoagulation","G-Probe Transscleral cyclophotocoagulation",{"date":170,"type":45},{"date":197,"type":45},"2020-01-30",{"date":199,"type":23},"2036-12-01",{"name":51,"class":52},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},"100377761","proteomic-and-metabolomic-lacrimal-fingerprint-in-diverse-pathologies-of-the-ocular-surface-100377761","NCT04198740","Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface","EML-MSO","Inclusion Criteria:\n\n* Patients with healthy corneas or suffering from one of these pathologies:\n\nDry eye syndrome; Infectious keratitis and\u002For conjunctivitis; Mucous membrane pemphigoid; Allergic conjunctivitis.\n\nExclusion Criteria:\n\n* Patients younger than 18 years old;\n* Patients incapable of giving informed consent.",{"count":209,"type":23},300,"OBSERVATIONAL","This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.",[213,214,215,216],"Dry Eye Syndrome","Infectious Keratoconjunctivitis","Mucous Membrane Pemphigoid","Allergic Conjunctivitis",[218,219,220,221],"Lacrimal fingerprint","Metabolomics","Proteomics","Ocular surface",{"date":170,"type":45},{"date":224,"type":45},"2020-02-01",{"date":226,"type":23},"2035-01",{"name":51,"class":52},2,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":100},"100435560","eus-cpn-with-and-without-bupivacaine-100435560","NCT04951804","EUS-CPN With and Without Bupivacaine","A Randomized Controlled Trial of Endoscopic Ultrasound Guided Celiac Plexus Neurolysis (EUS-CPN) With and Without Bupivacaine","EUS-NB","Inclusion Criteria:\n\n1. Malignant-appearing pancreatic mass, or proven pancreatic cancer involving the pancreatic genu, body, or tail\n2. Any level of abdominal or back pain considered to be potentially related to the mass:\n\n   1. New onset pain (\\\u003C3 months)\n   2. Constant\n   3. Centrally located\n   4. With or without irradiation to the back\n   5. No obvious other source of pain based on history and physical examination by the attending endosonographer\n3. No possibility of surgical management\n4. Signed, informed consent\n5. Celiac axis accessible for bilateral neurolysis at EUS.\n\nExclusion Criteria:\n\n1\\. Allergy to bupivacaine",{"count":238,"type":23},180,[26],"Endoscopic ultrasound (EUS) allows EUS-guided trans gastric injection of absolute alcohol around the base of the celiac plexus (celiac plexus neurolysis (EUS-CPN)), to help alleviate pain associated with pancreatic cancer.\n\nIt is standard procedure to inject bupivacaine immediately before injecting absolute alcohol, to theoretically prevent pain that may occur during and after the procedure. However, there are no data showing whether bupivacaine injection has any real influence on intra-procedural, immediate post-procedural, or long-term pain control. The injection of bupivacaine before the alcohol may have no effect, a synergistic effect, or an antagonistic effect, by diluting the alcohol, and reducing its neurolytic capacity. Inadvertent intravascular injection of bupivacaine may also cause irreversible cardiac arrhythmias and death.\n\nThe investigators therefore propose a randomized clinical trial to determine whether the exclusion of bupivacaine during EUS-guided CPN improves outcomes, or not.",[242],"Pancreatic Cancer",[242,244,245,246,247,248],"Celiac plexus neurolysis","Bupivacaine","Endoscopic ultrasound","With Bupivacaine","Without Bupivacaine","2026-04-20",{"date":168,"type":45},{"date":252,"type":45},"2021-10-07",{"date":254,"type":23},"2029-12",{"name":51,"class":52},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":24,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":100},"100633943","rescue-distal-thrombectomy-in-treatment-for-persistent-distal-occlusions-100633943","NCT07533253","Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions","Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy - A PHASE II Trial","2BE3-PhaseII","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute ischemic stroke with proximal large vessel occlusion (M1, M2, ICA, or basilar artery) treatable with mechanical thrombectomy\n* Presence of one or more persistent distal occlusions (M2-M4, A1-A5, or P1-P5) after successful proximal mechanical thrombectomy\n* The participant is considered suitable for either rescue distal mechanical thrombectomy or conservative management in the event of persistent distal occlusion\n* Informed consent obtained from the participant or authorized representative, in accordance with the protocol and local regulations\n\nExclusion Criteria:\n\n* Poor expected 3-month prognosis due to comorbid conditions\n* Opposition by the participant or, in emergency inclusion circumstances, by an authorized representative",{"count":265,"type":23},72,[26],"The goal of this clinical trial is to determine whether rescue distal mechanical thrombectomy can improve outcomes in patients with persistent distal occlusions after successful proximal mechanical thrombectomy for acute ischemic stroke.\n\nMany patients with acute ischemic stroke caused by large vessel occlusion undergo emergency treatment with proximal mechanical thrombectomy, which removes the main clot and restores flow in a large artery. However, in some patients, one or more smaller distal arteries remain occluded after successful proximal recanalization. It is not yet known whether treating these persistent distal occlusions improves angiographic or clinical outcomes.\n\nThis study will compare two approaches:\n\nRescue distal mechanical thrombectomy: an additional distal mechanical thrombectomy procedure is performed during the same endovascular session.\n\nConservative management: no additional distal endovascular intervention is performed after successful proximal mechanical thrombectomy.\n\nThe main questions the study aims to answer are:\n\n* Is rescue distal mechanical thrombectomy feasible in this setting?\n* Is it safe?\n* Does it improve angiographic and clinical outcomes?\n\nParticipants will be randomly assigned during the index endovascular procedure to one of the two study groups and will be followed with imaging and clinical assessments during hospitalization and at 90 days.\n\nApproximately 72 participants will take part in this study at the Centre hospitalier de l'Université de Montréal (CHUM).",[269],"Acute Ischemic Stroke",[271,272,273],"thrombectomy","endovascular treatment","distal occlusion","2026-04-14",{"date":276,"type":45},"2026-04-16",{"date":278,"type":23},"2026-09-01",{"date":280,"type":23},"2029-12-31",{"name":51,"class":52},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":24,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":100},"100474996","sting-mark-universal-fiducial-marker-system-100474996","NCT05465161","STING MARK Universal Fiducial Marker System","An Ex-Vivo Human Model Study for Proof of Concept, Usability, Reproducibility, Radio-Opacity and Marker Retention","StingMark","Inclusion Criteria:\n\n* Patients undergoing surgical resection of solid organs\n* Recipients of solid organ transplantation\n\nExclusion Criteria:\n\n* None",{"count":291,"type":23},100,[26],"Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters\u002Fneedles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.",[295],"Cancer","2026-04-10",{"date":298,"type":45},"2026-04-13",{"date":300,"type":45},"2022-02-28",{"date":302,"type":23},"2027-11-01",{"name":51,"class":52},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":24,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":100},"100608042","phase-1-kan-004-for-immune-related-diarrhea-or-colitis-100608042","NCT07196410","KAN-004 for Immune-Related Diarrhea or Colitis","A Phase I Study of KAN-004 in Patients With Immune-Related Diarrhea or Colitis","Inclusion Criteria:\n\n* Diagnosis of solid tumor treated with immune checkpoint inhibitor (≥1 cycle, ≤180 days since last cycle).\n* Clinical diagnosis of irColitis (CTCAE \\>grade 2).\n* Age ≥18 years\n* Able to ingest capsules.\n* Consent to provide blood and stool samples.\n* Accessible for treatment and follow-up.\n* Agreement to use highly effective contraception if of childbearing potential.\n\nExclusion Criteria:\n\n* Prior\u002Fconcurrent malignancy that could interfere with safety\u002Fefficacy assessment.\n* Colostomy.\n* Prior diagnosis of malabsorption.\n* Untreated chronic hepatitis B or C.\n* Solid organ transplant recipients.\n* HIV-positive status.\n* Pregnancy or breastfeeding.",{"count":312,"type":23},21,[112],"The goal of this clinical trial is to evaluate the safety and tolerability of KAN-004 in patients with immune-related colitis.",[316,317],"Colitis","Diarrhea Caused by Antitumor Drugs","2026-04-08",{"date":298,"type":45},{"date":321,"type":45},"2026-03-01",{"date":323,"type":23},"2030-12-31",{"name":51,"class":52},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":100},"100632632","phase-2-adaptive-radiotherapy-for-safe-hypofractionation-100632632","NCT07516210","Adaptive Radiotherapy for Safe Hypofractionation","Adaptive Radiotherapy for Safe Hypofractionation (ART-Hypo): A Bayesian Registry-Based Randomized Controlled Trial","ART-Hypo","Inclusion Criteria:\n\n\\- Enrolled in PERa registry (CHUM CER 17.0.32), consented to contact for investigational trials, consented to serve as control, and randomly selected to be offered the experimental intervention.\n\nExclusion Criteria:\n\n\\- For intact prostate stratum : 1. Contraindications to MRI (e.g., pacemaker, potentially mobile metal implant, claustrophobia). 2. Hip replacement, or other pelvic metalwork which causes significant artefact on MRI.",{"count":334,"type":23},264,[164],"This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2) external beam radiotherapy compared with standard-of-care (SOC) fractionation.\n\nConventional radiotherapy requires generous planning target volume (PTV) margins to account for inter-fraction anatomical variation, which increases radiation exposure to surrounding organs at risk (OARs) and may contribute to toxicity. Modern ART platforms using daily on-table imaging (kV-CBCT or MRI guidance) allow real-time contour adaptation and online plan re-optimization based on same-day anatomy. This approach enables margin reduction while maintaining target coverage and may permit safe hypofractionation.\n\nEligible patients enrolled in an institutional prospective registry will be randomized (1:1) to receive either SOC radiotherapy or hypofractionated ART across multiple pelvic disease strata (post-prostatectomy prostate cancer, intact prostate cancer, endometrial cancer, cervical cancer, and rectal cancer).\n\nThe primary objective is to demonstrate non-inferiority of hypofractionated ART compared with SOC in terms of cumulative incidence of Grade ≥2 toxicity (CTCAE v5). Secondary outcomes include acute and late toxicity, oncologic outcomes (progression-free survival, locoregional failure, distant metastases, overall survival), patient-reported outcomes, treatment efficiency, and dosimetric parameters.\n\nA Bayesian monitoring framework with pre-specified safety and futility stopping rules will be used to ensure patient safety and clinical equipoise throughout the trial.",[295,338,339,340,341],"Endometrial Cancer","Prostate Cancer","Cervical Cancer","Rectal Cancers","2026-04-02",{"date":344,"type":45},"2026-04-07",{"date":346,"type":23},"2026-05",{"date":348,"type":23},"2030-05",{"name":51,"class":52},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":358,"minAge":4,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":372,"locationsCount":100},"100620205","phase-2-external-beam-and-radioligand-radiotherapy-for-mcrpc-100620205","NCT07354594","External Beam and Radioligand Radiotherapy for mCRPC","Adaptive External Beam and Radioligand Radiotherapy for MEtaSTatic Castration Resistant Prostate Cancer (ARREST): a Phase II Registry-based RCT","ARREST","Inclusion Criteria:\n\n* Receiving 177Lu-PSMA for mCRPC\n* ECOG 0-1\n* Presence of a discernible metastatic burden suitable for EBRT\n* Receiving bone protective therapy\n\nExclusion Criteria:\n\n* no exclusions","MALE",{"count":360,"type":23},120,[164],"Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer. Administered intravenously, it enables targeted irradiation of PSMA-expressing tumor cells. However, 30-50% of patients derive limited benefit. This variability could be partly explained by heterogeneity in delivered dose across lesions, leading to under-treatment of certain metastases. The addition of targeted external beam radiotherapy (EBRT) may compensate for this underdosing by delivering a precise dose to insufficiently irradiated lesions.\n\nWe hypothesize that the addition of adaptive EBRT to ¹⁷⁷Lu-PSMA will reduce the incidence of skeletal-related events (pathologic fracture, spinal cord compression, surgery, or palliative radiotherapy) without increasing toxicity.\n\nAdaptive EBRT and RLT for mCRPC (ARREST) is a pragmatic registry-based phase 2, multi-center randomized controlled trial within the PERa prospective cohort (NCT03378856) planned to activate in 2026. Patients who are receiving SOC 177Lu-PSMA with targetable metastatic burden identified on imaging suitable for EBRT will be eligible. One hundred and twenty eligible patients will be randomized 1:1 to receive either SOC 177Lu-PSMA therapy alone (maximum 6 cycles) or to combined 177Lu-PSMA plus adaptive EBRT. Patients in the experimental arm will undergo FDG-PET at study entry and SPECT-CT after each cycle of radioligand therapy. Lesions selected for EBRT boost will be selected based on a set of criteria that include estimated suboptimal dose absorbed from 177LuPSMA, lesions demonstrating low PSMA but high FDG update, symptomatic lesions, and those at high risk for skeletal-related events. Selected lesions will receive single-fraction EBRT. Dose prescribed will range from 6-12 Gy with the ideal goal of a combined total biological effective dose of ≥50 Gy (α\u002Fβ = 5) with priority to dose limits for organs at risk.\n\nA maximum treatment time of 60 minutes is permitted for each adaptive EBRT treatment. Patients in the experimental arm that achieve complete response measured by 177Lu-SPECT-CT and PSA will pause ARREST and resume at progression. The primary endpoint is skeletal related events at 1 year. Secondary objectives include overall survival, 177Lu-SPECT-CT and PSA response, toxicity, and quality of life. The sample size is designed to detect a 12 month improvement in the rate of skeletal related events with a HR 0.61, one-sided alpha of 0.1 and 80% power.\n\nARREST is hypothesized to safely optimize tumor dose, offering a personalized hybrid approach that may lead to improved patient outcomes. In addition, this study will permit further understanding of these two distinct radiation delivery methods and their effect on tissues, thereby refining the relative biological effectiveness model for more precise treatment planning.",[364],"Prostate Cancer Metastatic Castration-Resistant",[366,367],"radiotherapy","radioligand therapy",{"date":318,"type":45},{"date":346,"type":23},{"date":371,"type":23},"2028-05",{"name":51,"class":52},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":358,"minAge":4,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":100},"100474422","phase-2-ablative-radiotherapy-to-consolidate-maximal-systemic-response-in-metastatic-prostate-cancer-anchor-prostate-100474422","NCT05457699","Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)","ANCHORProstate","Inclusion Criteria:\n\n* Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate.\n* Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy.\n* PSA non-progressing\n* ECOG 0-2\n* Metastatic disease suitable for MDRT.\n* Primary tumor must have received definitive local treatment (surgery or radiotherapy) with no evidence of local recurrence, or be planned for treatment at the time of MDRT.\n\nExclusion Criteria:\n\n* Planned intermittent systemic therapy.\n* Planned radio-ligand therapy.",{"count":381,"type":23},80,[164],"This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy, defined by the absence of PSA progression, and who are eligible for MDRT. All eligible subjects will be enrolled into the registry and followed longitudinally for oncologic and toxicity outcomes.\n\nFrom this registry, patients will be randomly selected (1:1) to be offered the experimental arm, which consists of MDRT delivered to metastatic sites identified on imaging in patients who have already initiated systemic therapy (Figure 1). Those not selected will continue to receive standard of care systemic therapy +\u002F- standard of care radiotherapy if clinically indicated. Nor patients or physicians will be blinded.\n\nFollowing the initial course of MDRT, prostate-specific antigen (PSA) will be measured, with a minimum assessment at 3 months. This PSA value will be used to determine whether the PSA level has decreased below 0.2 ng\u002FmL. If the PSA remains ≥ 0.2 ng\u002FmL, repeat PSMA-PET will be performed, and a second course of MDRT will be delivered to consolidate residual metastatic lesions.\n\nIn this phase II real-world randomized trial, we will determine if AnChoRing (Addition of MDRT for consolidation of response) sites of PSMA PET visible disease when responding to systemic therapy improves the proportion of patients achieving a PSA \\\u003C 0.2 ng\u002FmL and extends failure-free survival compared to the standard of care.",[385],"Prostate Cancer Metastatic",{"date":318,"type":45},{"date":388,"type":45},"2022-12-30",{"date":390,"type":23},"2030-07-30",{"name":51,"class":52},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":19,"minAge":398,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":24,"phases":401,"briefSummary":403,"conditions":404,"keywords":406,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":100},"100418168","phase-4-prospective-study-on-the-role-of-intravenous-unfractionated-heparin-following-digital-replantation-and-revascularization-100418168","NCT04725201","Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization","Inclusion Criteria:\n\n* All replantation and revascularization patients who are accepted into the CEVARMU program at the Centre hospitalier de l'Université de Montréal\n\nExclusion Criteria:\n\n* Patients on anticoagulants, other than ASA, prior to admission (i.e. Coumadin, Eliquis, Pradaxa, Plavix, or similar medications)\n* Patients with a contraindication for heparin (e.g. coagulopathy, acute ulcers, thrombocytopenia, severe liver damage, shock)\n* Patients who suffered an amputation in the level of the carpal tunnel and proximal to it\n* Patients who experienced a degloving injury","14 Years",{"count":400,"type":23},188,[402],"PHASE4","The purpose of this study is to determine the effectiveness of therapeutic dose intravenous heparin at improving replantation\u002Frevascularization success and its indications (if any) in participants who have suffered traumatic digital amputation. Digital replantation\u002Frevascularization success will be assessed in participants who receive continuous intravenous drip of thromboprophylactic heparin at a therapeutic dose (i.e. modifies INR to the desired range) contrasted to those who do not receive therapeutic dose heparin (i.e. does not modify INR to the desired range). In the study, replantation\u002Frevascularization success is defined as a clearly viable digit at the time of discharge. Secondary objectives include assessing postoperative complications associated with heparin use, such as bleeding, hematoma or heparin induced thrombocytopenia. The investigators would also assess the impact of categorical variables such as smoking status, mechanism of injury and comorbidities, on digital survival.",[405],"Amputation; Traumatic, Hand",[407,408,409,410],"Replantation","Revascularization","Unfractionated heparin","Finger","2026-03-27",{"date":342,"type":45},{"date":414,"type":45},"2021-05-24",{"date":416,"type":23},"2027-05-01",{"name":51,"class":52},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":24,"phases":428,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":4},"100631160","comparison-of-two-surgical-techniques-for-the-treatment-of-trigger-fingers-longitudinal-opening-versus-complete-a1-pulley-release-100631160","NCT07497061","Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pulley Release","Randomized Clinical Trial Comparing Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pulley Release.","TRIGGER","Inclusion Criteria:\n\n* Patients requiring surgical intervention for the treatment of a trigger finger\n* Patients able to provide informed consent\n\nExclusion Criteria:\n\n* History of surgery for trigger finger correction on the same finger\n* Patients requiring simultaneous surgery for more than one trigger finger",{"count":427,"type":23},236,[26],"Trigger finger is a pathology of the flexor tendons caused by inflammation of the tendon or its sheath, leading to pain, nodules, fibrosis, and limited mobility. Surgical treatment aims to release the space at the level of the A1 pulley, either through longitudinal opening (the standard technique, but associated with recurrence rates of approximately 7.7%) or through complete resection, an emerging approach that may reduce recurrences and the need for reoperations. However, comparative data remain limited, justifying further investigation. This project therefore aims to compare these two surgical techniques to determine which one results in the lowest recurrence rate and to assess their functional outcomes (pain, range of motion). The primary hypothesis is that A1 pulley resection reduces recurrences after one year, while the secondary hypothesis is that there is no significant difference in postoperative pain or mobility.",[431,432],"Trigger Digit","Trigger Finger",[434,435,436],"A1 pulley resection","surgical technique for trigger finger","longitudinal opening of the A1 pulley","2026-03-26",{"date":439,"type":45},"2026-03-31",{"date":441,"type":23},"2026-04-01",{"date":443,"type":23},"2029-04-01",{"name":51,"class":52},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":475,"locationsCount":100},"100542641","early-detection-of-liver-cancer-by-qus-100542641","NCT06345508","Early Detection of Liver Cancer by QUS","Quantitative Ultrasound to Improve Detection and Diagnosis of Liver Cancer","QUS in HCC","Inclusion Criteria:\n\n\\- Adult patients scheduled for US- or MRI-based surveillance of HCC or undergoing MRI-based imaging for characterization of liver nodules as part of their clinical standard of care.\n\nExclusion Criteria:\n\n\\- Patients with prior locoregional or systemic therapy.",{"count":454,"type":23},328,"Worldwide, liver cancers are the third most common cause of cancer mortality. Even when liver cancer is suspected by blood tests, imaging is required to determine the location, size, and extent of disease. Medical societies therefore recommend surveillance with ultrasound every 6 months in at-risk patients. However, a key challenge to improving the survival is that ultrasound may miss half of early-stage liver cancers, thus diagnosis must rely on additional tests such as computed tomography (CT), magnetic resonance imaging (MRI), or biopsy. Hence, there is a clear need to improve the ability to detect liver cancers, especially with ultrasound. The investigator's team proposes novel ultrasound approaches to detect cancer nodules invisible on conventional ultrasound based on differences in mechanical and structural properties between liver and tumor. Improving detection is critical because liver cancer can be cured only if detected at an early stage, as shown by improvements in survival rates in patients enrolled in surveillance programs. The investigator's multi-disciplinary, national, and international team includes experts in clinical fields (hepatology, oncology, radiology, pathology), basic sciences (engineering, medical physics, machine learning, biostatistics), and patient partnership. The investirgator will apply the methodology of patient partner recruitment and collaborate with the Centre of Excellence on Partnership with Patients and the Public to select potential new collaborators. This will permit this project to be informed at every stage by patient and family perspectives, ensuring that the results of this project will be more robust, impactful, and aligned with the priorities, needs and experiences of those who live with liver cancer. The investigator submits a research proposal focused on advanced imaging techniques because imaging constitutes a foundation for surveillance, diagnosis, staging, treatment selection and assessment of treatment response in patients with liver cancer.",[457,458],"Hepatocellular Carcinoma","Liver Cancer",[460,461,462,463,464,465,466,124,467,468],"Ultrasound","Quantitative ultrasound (QUS)","Liver cancer","Hepatocellular carcinoma","Elastography","Viscoelastography","Screening","Diagnosis","Diagnostic performance","2026-03-18",{"date":471,"type":45},"2026-03-20",{"date":473,"type":45},"2024-08-20",{"date":254,"type":23},{"name":51,"class":52},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":100},"100575111","secondary-prevention-and-management-of-myocardial-injury-after-noncardiac-surgery-synergy-pilot-trial-100575111","NCT06768034","SecondarY Prevention and maNagement of Myocardial Injury aftER Noncardiac surGerY (SYNERGY) Pilot Trial","A Pilot Pragmatic Randomized Controlled Trial Evaluating Secondary Cardiovascular Prevention Therapies in Patients Who Had a Myocardial Injury After Noncardiac Surgery to Prevent Major Cardiovascular Events","Inclusion Criteria:\n\n1. Have undergone noncardiac surgery,\n2. Had a myocardial injury after noncardiac surgery with a presumed ischemic mechanism and without an overt nonischemic precipitating etiology (e.g., sepsis)\n3. Provide written informed consent to participate in the SYNERGY pilot trial.\n\nExclusion Criteria:\n\n1. already on 2 of 3 secondary cardiovascular prevention medications (i.e., antiplatelet, statin, and\u002For angiotensin-converting enzyme inhibitor (ACEI)\u002Fangiotensin II receptor blocker (ARB)\n2. patients with contraindication to statins (i.e., decompensated or Child-Pugh C cirrhosis, acute liver failure, elevated AST\u002FALT greater than 2-fold the normal upper limit, previous demonstrated statin hypersensitivity, allergy, or statin-related myopathy);\n3. patients with contraindication to antiplatelet therapy (i.e., active or recent \\\u003C1-month peptic ulcer disease, esophageal or gastric variceal disease, history of intracranial or intraspinal hemorrhage, significant thrombocytopenia with platelet count \\\u003C50 × 109\u002FL),\n4. patients with contraindication to ACEI and ARB therapy (i.e, hypersensitivity or allergy to ACEI or ARB);\n5. Previously enrolled in the SYNERGY pilot trial,\n6. Considered unreliable or unable to complete the trial procedures.",{"count":291,"type":23},[26],"Cardiac complications, particularly myocardial injury after noncardiac surgery (MINS), significantly contribute to 30-day mortality, affecting about 1 in 10 patients after noncardiac surgery. Despite its prevalence and serious implications, there is no consensus on managing myocardial injury after noncardiac surgery in clinical practice. Interventions commonly used for cardiovascular prevention in patients who had a heart attack outside of a surgery context could also be beneficial in patient with MINS. This pilot study trial aims to gather feasibility data, such as recruitment rates and intervention adherence that will guide on the design and inform on sample size of a future study with large pragmatic randomized controlled trial on the impact of systematic referral for secondary cardiovascular prevention on outcomes in patients who had a MINS.",[487],"Myocardial Injury After Noncardiac Surgery (MINS)",[489,490,491],"Noncardiac surgery","Secondary cardiovascular prevention","Randomized controlled trial","2026-03-17",{"date":494,"type":45},"2026-03-19",{"date":496,"type":23},"2026-04",{"date":498,"type":23},"2027-11",{"name":51,"class":52},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":100},"100512165","defining-a-technique-for-the-use-of-cryogenic-catheters-for-biopsy-and-ablation-for-the-diagnostic-and-treatment-of-pulmonary-lesions-an-ex-vivo-human-lung-model-study-100512165","NCT05948904","Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study.","CT0129","Inclusion Criteria:\n\n* Patients undergoing lung transplant surgery\n\nExclusion Criteria:\n\n* Organ donor ineligible to donate lungs\n* Healthy individuals",{"count":508,"type":23},200,[26],"Developing a standardized methodology for the use of novel cryogenic catheters for transbronchial cryobiopsy and cryoablation of pulmonary lesions.",[512],"Lung Diseases",[514,515,516,517],"Lung","cryobiopsy","cryoablation","transbronchial intervention",{"date":469,"type":45},{"date":520,"type":45},"2023-11-03",{"date":522,"type":23},"2027-04-01",{"name":51,"class":52},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":100},"100513918","validation-of-a-system-using-aerosol-glycerine-to-detect-and-localize-intraoperatively-pulmonary-air-leaks-100513918","NCT05971719","Validation of a System Using Aerosol Glycerine to Detect and Localize Intraoperatively Pulmonary Air Leaks","CT0136","Inclusion Criteria:\n\n* Patients undergoing lung transplant surgery\n* Organ donor ineligible to donate lungs\n\nExclusion Criteria:\n\n* Healthy individuals",{"count":508,"type":23},[26],"Air leaks represent one of the most common complications and postoperative morbidity in thoracic surgery. Air leaks have been associated with the largest preventable morbidity associated with increased costs following lobectomy (typically related to increased length of stay). However, the standard used to detect and localize the air leaks, the submersion test, is not suitable for the standard surgical procedure, Video Assisted Thoracic Surgery. Considering the prevalence of this complication and the absence of a surgical standard of care for such complications, the aim of this study is to develop a system to create and send a glycerine aerosol smoke in the lungs of the patient. The smoke is visible with standard laparoscope and will flow though the pulmonary leak, thereby reducing postoperative surgical complications, morbidity, and length of stay for patients undergoing pulmonary resection.",[535],"Air Leak From Lung",{"date":469,"type":45},{"date":538,"type":45},"2023-07-20",{"date":540,"type":23},"2027-07-01",{"name":51,"class":52},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":100},"100504924","air-leak-detection-and-treatment-100504924","NCT05854654","Air Leak Detection and Treatment","Defining Novel Strategies for the Diagnosis and Treatment of Intraoperative Air Leaks: An Ex-Vivo Human Lung Model Study","CT0128",{"count":508,"type":23},[26],"Developing a methodology to detect, quantify and treat air leaks intraoperatively using a bio-adhesive, to thereby reduce postoperative surgical complications, morbidity, and length of stay for patients undergoing pulmonary resection.",[535],{"date":469,"type":45},{"date":555,"type":45},"2023-05-02",{"date":522,"type":23},{"name":51,"class":52},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":567,"briefSummary":569,"conditions":570,"keywords":572,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":100},"100439201","phase-3-choline-pet-exploratory-study-assessing-the-potential-role-of-f-choline-pet-imaging-in-new-and-emerging-indications-100439201","NCT04999215","Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications","F-choline","Inclusion Criteria:\n\n* Any patient with a known or suspected condition in which F-choline PET imaging might provide clinically useful information.\n\nExclusion Criteria:\n\n* Pregnancy\n* Breastfeeding woman, unwilling to discontinue breastfeeding for 48 hours\n* Known allergy to F-choline or any excipients\n* Pediatric patient (\\\u003C 18 years old)",{"count":566,"type":23},500,[568],"PHASE3","Choline is an important building block of phospholipids in cell membranes. Certain cancers and medical conditions are known to demonstrate increased absorption and incorporation of choline into their cell membranes. 18-F-fluorocholine (F-choline) and 11-C-choline (C-choline) are diagnostic positron emission tomography (PET) radiotracers that can be used to image, in vivo, the metabolism of choline. Both tracers have been extensively studied in prostate cancer and C-choline has obtained US FDA approval for the investigation of recurrent prostate cancer. F-choline is currently not approved for clinical use by the FDA or Health Canada, but it offers many advantages over C-choline due to its better physical characteristics (mainly due to its positron range, shorter and longer half-life). In recent years, reports have started to emerge on broader potential applications of choline PET imaging, particularly for imaging parathyroid adenomas, certain cervical cancers and certain liver cancers.\n\nThe main objective is to discover and explore potential new and emerging indications in which F-choline could play a role and provide clinically relevant information.\n\nSecondary objectives are 1) To assess the safety of F-choline PET imaging using F-choline produced at the CRCHUM; 2) assess changes in patient\u002Fdisease management following F-choline PET imaging.\n\nResearchers hypothesize that F-choline will provide useful and incremental clinical information in a variety of conditions, and outperform the \"standard\" workup in numerous conditions.\n\nF-Choline PET exams will be performed on hybrid PET\u002FCT scanners according to standard procedures. These examinations could be repeated at the discretion of the treating physician (up to a maximum of 4 exams per year) if the treating physician and the research team deem this could provide additional clinically useful information (for example, by helping to assess response to newly started therapy).\n\nThe results will be provided to the attending physician and any new knowledge could lead to a change in treatment or an investigation of the condition that prompted enrollment in the study.",[571],"Lesion With Known or Suspected F-choline Uptake",[573,574,468],"Imaging","F-choline PET",{"date":494,"type":45},{"date":577,"type":45},"2022-08-01",{"date":579,"type":23},"2032-08-01",{"name":51,"class":52},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":19,"minAge":589,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":592,"conditions":593,"keywords":597,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":607,"locationsCount":608},"100437217","vascular-events-in-patients-undergoing-same-day-noncardiac-surgery-valiance-study-100437217","NCT04973397","Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study","Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study - A Prospective Observational Cohort Study Evaluating Major Cardiovascular and Adverse Events in Patients Undergoing Elective Same-day Noncardiac Surgery","VALIANCE","Inclusion Criteria:\n\n* 45-64 years of age with at least one risk factor, or ≥65 years of age;\n* undergoing elective noncardiac same-day surgery;\n* planned duration in the operating room 60 minutes or more;\n* provided written consent.\n\nExclusion Criteria:\n\n* intervention does not require the presence of an anesthesiologist;\n* procedure is performed by a nonsurgical specialty (e.g., gastroenterology, pneumology, radio-oncology or radiology);\n* intervention is an ophthalmologic procedure;\n* previously enrolled in the VALIANCE study.","45 Years",{"count":591,"type":23},15000,"The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-day noncardiac surgery. The main objective of this study is to inform on the incidence and risk factors of cardiovascular and other adverse events after same-day surgery and to develop risk prediction tools to better inform on the risk and selection of patients undergoing same-day surgery.",[594,595,596],"Preoperative Care","Surgery--Complications","Myocardial Infarction",[594,598,599,600,601,602],"Surgery","Postoperative complications","Same-day surgery","Ambulatory surgery","Outpatient surgery",{"date":494,"type":45},{"date":605,"type":45},"2021-11-17",{"date":98,"type":23},{"name":51,"class":52},16,{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":358,"minAge":20,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":24,"phases":617,"briefSummary":618,"conditions":619,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":624,"locationsCount":100},"100331400","phase-3-psma-pet-deep-radiomic-biomarkers-of-progression-and-response-prediction-in-prostate-cancer-100331400","NCT03594760","PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer","Inclusion Criteria:\n\n* Patients with prostate cancer, being followed and treated at CHUM, whose treating physician at CHUM has requested a PSMA-PET scan.\n\nExclusion Criteria:\n\n* Claustrophobia\u002Finability to complete imaging procedure.",{"count":616,"type":23},1000,[568],"Prostate cancer (PCa) is the most common non-skin malignancy and the third leading cause of cancer death in North American men. The accurately mapped metastatic state is a necessary prerequisite to guiding treatment in practice and in clinical trials. Imaging biomarkers (BMs) can provide information on disease volume and distribution, prognosis, changes in biologic behavior, therapy-induced changes (both responders and non-responders), durations of response, emergence of treatment resistance, and the host reaction to the therapies.\n\nOf particular relevance to metastatic prostate cancer is the emergence of a promising imaging technique involving new prostate specific membrane antigen (PSMA) positron emission tomography (PET) tracers. This approach has demonstrated higher sensitivity in detecting metastases, prior to and during therapy, than current imaging standard of care (CT and bone scan), and is not widely clinically available outside of the research realm in North America.\n\nPositron emission tomography \u002F computer tomography (PET\u002FCT) is a nuclear medicine diagnostic imaging procedure based on the measurement of positron emission from radiolabeled tracer molecules in vivo. PSMA is a homodimeric type II membrane metalloenzyme that functions as a glutamate carboxypeptidase\u002Ffolate hydrolase and is overexpressed in PCa. PSMA is expressed in the vast majority of PCa tissue specimens and its degree of expression correlates with a number of important metrics of PCa tumor aggressiveness including Gleason score, propensity to metastasize and the development of castration resistance.\n\n\\[18F\\]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe. Studies employing second-generation PSMA PET\u002FCT imaging in men with biochemical progression after definitive therapy suggest detection of metastases in over 60% of men imaged.\n\nDeep learning is defined as a variant of artificial neural networks, using multiple layers of 'neurons'. Deep learning has been investigated in medical imaging in numerous applications across organ systems. In oncology, basic artificial neural networks to support decision-making have previously been developed retrospectively in breast cancer and prostate cancer, but have not been validated or integrated prospectively. Novel data-driven methods are needed to predict outcomes as early as possible in order to guide the duration and the aggressiveness of a particular therapy. They are also needed for optimal patient selection based on the patient's response to a given therapy.\n\nHere the investigators hypothesize that the combination of a highly performing prostate cancer imaging technique combined with machine learning has high potential. The main objective of this study is to acquire PSMA-PET data in patients with prostate cancer who receive treatment and follow-up in order to enable the discovery of predictive imaging biomarkers through deep learning techniques.",[339],{"date":494,"type":45},{"date":622,"type":45},"2018-12-01",{"date":254,"type":23},{"name":51,"class":52},""]